Flu Hospitalization Rate Week 26: Market Near Certain on 85-90 Range

The CDC’s weekly flu surveillance data moved this market decisively on July 3. The contract tracking the flu hospitalization rate for Week 26 of 2026 jumped sharply after new surveillance figures pointed directly at the 85–90 range. At 97.7% implied probability, the market has effectively concluded this question. Here’s what the measurements are telling us: the data landed, traders read it, and the price followed within hours.

The market question asks whether the CDC-reported flu hospitalization rate for Week 26, 2026 falls within the 85–90 band. The YES contract trades at $0.98, the NO contract at $0.02. The market resolves July 10, 2026. Total volume stands at $1,144, all of it placed in the last 24 hours.

How the Week Twenty-Six Flu Hospitalization Contract Works

This contract resolves YES if the CDC’s official flu hospitalization rate for epidemiological Week 26 of 2026 falls within the 85–90 range (per 100,000 population). CDC FluView, the agency’s weekly influenza surveillance platform, publishes hospitalization data each Friday. That publication date aligns directly with this contract’s July 10 resolution deadline.

• YES ($0.98, ~98% implied probability): CDC Week 26 hospitalization rate lands between 85 and 90 per 100,000.
• NO ($0.02, ~2% implied probability): The rate falls outside that range, into any adjacent band including 80–85, 90–95, or another interval.

A NO payout requires the rate to miss the 85–90 window entirely. That means either CDC revises a preliminary figure downward into the 80–85 range, or the rate climbs above 90. With summer flu activity typically near seasonal floor levels and the July 3 data already pointing inside this band, the window for NO is extremely narrow. The market is pricing uncertainty, not science, and right now there is very little of either.

Sponsored Partner

Momentum and Market Signals

The momentum composite tells a clear story. The trend score sits at 10.20, the 1-hour change is flat at 0.0%, and the 24-hour price action shows the contract moved 47.5% on July 3. That single-day surge was almost certainly triggered by a CDC FluView data release or a preliminary hospitalization figure that confirmed the 85–90 range. Once a science contract reaches this price level on actual data, it rarely retreats.

Total volume is $1,144, with all of that flowing in the last 24 hours. Liquidity sits at $6,036. Volume below $1 million means this contract can reprice sharply on any new CDC revision or data correction. The market is thin, but at 97.7%, there is little capital incentive to bet against a near-confirmed measurement.

• The July 3 price surge of 47.5% connects directly to new CDC flu surveillance data confirming the 85–90 hospitalization range for Week 26.
• The 1-hour flatline at 0.0% signals the market has absorbed the data and reached equilibrium at $0.98.
• Liquidity of $6,036 means any late data revision by CDC could move this contract more than the current odds suggest.
• The 24-hour volume of $1,144 reflects the full market trading history, concentrated in one event-driven session.
• The trend score of 10.20 reflects sustained directional momentum with no reversal signal present.

Lines Analysis: The CDC Data and What Could Still Move This

The data doesn’t care about the politics, and here the data has spoken. CDC FluView Week 26 surveillance figures drove a 47.5% price jump on July 3. That kind of single-session move on a science contract reflects one thing: a measurement that confirmed trader expectations. The 85–90 hospitalization rate range aligns with typical late-June flu patterns, when influenza activity in the US drops toward its annual low after peak winter transmission ends.

The path to NO runs through a CDC data revision. If FluView publishes a corrected Week 26 figure that shifts the rate below 85 or above 90, the contract reprices instantly. CDC does occasionally revise preliminary hospitalization estimates as hospital reporting catches up. That revision risk is real but small, typically affecting margins of one to two units, not eight to ten. A revision large enough to push the rate outside the 85–90 window would be exceptional.

• CDC FluView publishes final Week 26 data by July 10: any upward or downward revision above two units would reprice the NO contract.
• A late surge in flu hospitalizations driven by a novel variant or regional outbreak before July 10 could push the rate above 90.
• Downward revision risk exists if hospital reporting was initially overcounted, potentially shifting the rate into the 80–85 band.
• No revision announcement from CDC in the 24 hours since the July 3 data release supports the current 97.7% implied probability.
• The July 10 resolution deadline matches CDC’s weekly Friday publication schedule, leaving one more data confirmation window.

The $1,144 in total volume is thin by prediction market standards. That matters less here because the measurement is close to final. What the data favors is clear: the 85–90 range has been confirmed by CDC’s Week 26 surveillance figures, and the market reflects that confidence at 97.7%. The only open question is whether a revision changes the picture before July 10.

NEAR-CERTAIN YES

CDC Week 26 flu surveillance data already points inside the 85–90 hospitalization range, and the July 3 price surge confirms traders read those figures the same way. A data revision before July 10 is the only credible path to a different outcome.

What the market says: At 97.7% implied probability, the market has priced this as settled. The thin volume means a late CDC revision could create brief volatility, but the resolution date of July 10 leaves minimal runway for the fundamentals to shift.

Key unknown: The single most important event before resolution is the final CDC FluView Week 26 publication on or before July 10, 2026, and whether it confirms, revises, or corrects the preliminary hospitalization figure that drove the July 3 price move.